Table 2.

Representative primary and secondary endpoints and other important outcome variables comparing fosphenytoin (FOS) versus placebo in canine status epilepticus (CSE).

Endpoint/variable	FOS Group (n=22)	Placebo (n=9)	p-value
% responders at 2 hours	21/22 (95%)	5/9 (55%)	0.017*
% responders at 12 hours	14/22 (64%)	2/9 (22%)	0.043*
# episodes of motor seizures > 5 mins 1st 12 hours	1/22 (4.5%)	0/9 (0%)	0.71
Mean # seizures 12h post Tx (range)	0.61 (0–4)	1.54 (0–4)	0.020*
Vomiting	7/22 (32%)	0/9 (0%)	0.065
In-hospital mortality	3/22 (13%)	1/9 (11%)	0.63
Arrhythmia during or post infusion	2/22 (9%)	0/9 (0%)	0.50

Statistically Significant Differences Indicated with *